Clinical Trial

Multi-Arm Optimization of Stroke Thrombolysis (MOST): A Blinded, Randomized Controlled Adaptive, Multi-Arm, Adjunctiive-Thrombolysis Efficacy Trial in Ischemic Stroke

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with 0.9mg/kg IV rt-PA within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care.


Principal Investigator Patricia Fernandez, MD
Sponsor National Institute of Neurological Disorders and Stroke
Type of Trial Prospective/Interventional